Novel Isoindolone Compounds as HPK1 Inhibitors for Treating Cancer.
作者信息
Sabnis Ram W
机构信息
Smith, Gambrell & Russell LLP, 1105 W. Peachtree Street NE, Suite 1000, Atlanta, Georgia 30309, United States.
出版信息
ACS Med Chem Lett. 2022 Jan 12;13(2):156-157. doi: 10.1021/acsmedchemlett.1c00725. eCollection 2022 Feb 10.
Abstract
摘要
相似文献
1
Novel Isoindolone Compounds as HPK1 Inhibitors for Treating Cancer.新型异吲哚酮化合物作为用于治疗癌症的HPK1抑制剂
ACS Med Chem Lett. 2022 Jan 12;13(2):156-157. doi: 10.1021/acsmedchemlett.1c00725. eCollection 2022 Feb 10.
2
Novel Diaminopyrimidine Carboxamides as HPK1 Inhibitors for Treating Cancer.新型二氨基嘧啶甲酰胺类化合物作为治疗癌症的HPK1抑制剂
ACS Med Chem Lett. 2023 Jun 21;14(7):899-900. doi: 10.1021/acsmedchemlett.3c00249. eCollection 2023 Jul 13.
3
Novel Tetrahydropyrido[3,4-]pyrimidines as HPK1 Inhibitors for Treating Cancer, Inflammatory, and Autoimmune Diseases.新型四氢吡啶并[3,4-]嘧啶类化合物作为用于治疗癌症、炎症和自身免疫性疾病的HPK1抑制剂
ACS Med Chem Lett. 2024 Jan 31;15(3):318-319. doi: 10.1021/acsmedchemlett.4c00023. eCollection 2024 Mar 14.
4
Development of a series of quinazoline-2,5-diamine derivatives as potent hematopoietic progenitor kinase 1 (HPK1) inhibitors.一系列喹唑啉-2,5-二胺衍生物作为有效的造血祖细胞激酶1（HPK1）抑制剂的开发。
Eur J Med Chem. 2023 Feb 15;248:115064. doi: 10.1016/j.ejmech.2022.115064. Epub 2022 Dec 30.
5
Inhibitors of immuno-oncology target HPK1 - a patent review (2016 to 2020).免疫肿瘤学抑制剂靶向 HPK1 的专利研究（2016 年至 2020 年）。
Expert Opin Ther Pat. 2021 Oct;31(10):893-910. doi: 10.1080/13543776.2021.1924671. Epub 2021 May 20.
6
The development of small-molecule inhibitors targeting HPK1.靶向HPK1的小分子抑制剂的研发
Eur J Med Chem. 2022 Dec 15;244:114819. doi: 10.1016/j.ejmech.2022.114819. Epub 2022 Oct 4.
7
Discovery of an Allosteric, Inactive Conformation-Selective Inhibitor of Full-Length HPK1 Utilizing a Kinase Cascade Assay.利用激酶级联测定法发现全长 HPK1 的别构、无活性构象选择性抑制剂。
Biochemistry. 2021 Oct 19;60(41):3114-3124. doi: 10.1021/acs.biochem.1c00486. Epub 2021 Oct 5.
8
HPK1 as a novel target for cancer immunotherapy.HPK1 作为癌症免疫治疗的一个新靶点。
Immunol Res. 2012 Dec;54(1-3):262-5. doi: 10.1007/s12026-012-8319-1.
9
Hematopoietic Progenitor Kinase 1 in Tumor Immunology: A Medicinal Chemistry Perspective.造血祖细胞激酶 1 在肿瘤免疫学中的作用：从药物化学角度看。
J Med Chem. 2022 Jun 23;65(12):8065-8090. doi: 10.1021/acs.jmedchem.2c00172. Epub 2022 Jun 13.
10
Discovery of Macrocycle-Based HPK1 Inhibitors for T-Cell-Based Immunotherapy.用于基于T细胞的免疫疗法的大环类HPK1抑制剂的发现。
J Med Chem. 2023 Jan 12;66(1):611-626. doi: 10.1021/acs.jmedchem.2c01551. Epub 2022 Dec 21.
引用本文的文献
1
Novel Diaminopyrimidine Carboxamides as HPK1 Inhibitors for Treating Cancer.新型二氨基嘧啶甲酰胺类化合物作为治疗癌症的HPK1抑制剂
ACS Med Chem Lett. 2023 Jun 21;14(7):899-900. doi: 10.1021/acsmedchemlett.3c00249. eCollection 2023 Jul 13.
本文引用的文献
1
Advanced Nanotheranostics of CRISPR/Cas for Viral Hepatitis and Hepatocellular Carcinoma.CRISPR/Cas 系统的先进纳米诊疗学在病毒性肝炎和肝细胞癌中的应用
Adv Sci (Weinh). 2021 Dec;8(24):e2102051. doi: 10.1002/advs.202102051. Epub 2021 Oct 19.
2
Bidirectional feedback between BCR signaling and actin cytoskeletal dynamics.BCR 信号转导与肌动蛋白细胞骨架动态之间的双向反馈。
FEBS J. 2022 Aug;289(15):4430-4446. doi: 10.1111/febs.16074. Epub 2021 Jun 30.
3
Reprogramming the anti-tumor immune response via CRISPR genetic and epigenetic editing.通过CRISPR基因和表观遗传编辑重新编程抗肿瘤免疫反应。
Mol Ther Methods Clin Dev. 2021 Apr 24;21:592-606. doi: 10.1016/j.omtm.2021.04.009. eCollection 2021 Jun 11.
4
Small molecule approaches to treat autoimmune and inflammatory diseases (Part I): Kinase inhibitors.小分子治疗自身免疫和炎症性疾病的方法（第一部分）：激酶抑制剂。
Bioorg Med Chem Lett. 2021 Apr 15;38:127862. doi: 10.1016/j.bmcl.2021.127862. Epub 2021 Feb 18.
5
A perspective on HPK1 as a novel immuno-oncology drug target.HPK1 作为一种新型免疫肿瘤学药物靶点的观点。
Elife. 2020 Sep 8;9:e55122. doi: 10.7554/eLife.55122.
6
Ready for Repair? Gene Editing Enters the Clinic for the Treatment of Human Disease.准备好进行修复了吗？基因编辑进入临床用于治疗人类疾病。
Mol Ther Methods Clin Dev. 2020 Jul 3;18:532-557. doi: 10.1016/j.omtm.2020.06.022. eCollection 2020 Sep 11.
Zotero 插件